Literature DB >> 7022235

Clinical course of patients with scleroderma renal crisis treated with captopril.

E T Zawada, P J Clements, D A Furst, H A Bloomer, H E Paulus, M H Maxwell.   

Abstract

Since it has been suggested that the renin-angiotensin axis may play an important role in the severe hypertension and in the acute renal deterioration in scleroderma, we sought to determine the effectiveness of angiotensin blockade in the treatment of this disorder. Captopril controlled blood pressure successfully and easily in 4 consecutive patients with scleroderma renal crisis. Mean serum creatinine was 3.5 mg/dl after scleroderma renal crisis immediately prior to captopril. The first patient required maintenance hemodialysis because of progression to advanced renal failure before captopril was available. However, in this patient oliguric renal failure was changed to nonoliguric renal failure immediately after beginning therapy. Serum creatine stabilized in the other 3 patients. Serum creatinine peaked at 4.7 mg/dl, but then progressively improved to 3.5 mg/dl 12 weeks after captopril was begun. None of the other 3 patients required any form of dialysis during the scleroderma renal crises. Mean survival of these 4 patients was significantly greater than that of the 9 previous patients with scleroderma crisis. These observations confirm that angiotensin blockade with captopril is effective therapy to prevent renal deterioration, to control blood pressure and prolong survival in scleroderma patients with renal crisis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7022235     DOI: 10.1159/000182028

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  9 in total

Review 1.  Scleroderma renal crisis: new insights and developments.

Authors:  Elisa Y Rhew; Walter G Barr
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

2.  Benign outcome of hypertensive renal crisis in scleroderma.

Authors:  M H Arnold; R Robinson
Journal:  Ann Rheum Dis       Date:  1989-02       Impact factor: 19.103

Review 3.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

4.  The CREST syndrome--successful reduction of pulmonary hypertension by captopril.

Authors:  P J Prouse; A Lahiri; J M Gumpel
Journal:  Postgrad Med J       Date:  1984-10       Impact factor: 2.401

Review 5.  Scleroderma renal crisis and renal involvement in systemic sclerosis.

Authors:  Thasia G Woodworth; Yossra A Suliman; Wendi Li; Daniel E Furst; Philip Clements
Journal:  Nat Rev Nephrol       Date:  2016-09-19       Impact factor: 28.314

Review 6.  The scleroderma kidney: progress in risk factors, therapy, and prevention.

Authors:  Guillaume Bussone; Alice Bérezné; Vincent Pestre; Loïc Guillevin; Luc Mouthon
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

Review 7.  Kidney involvement in systemic sclerosis: From pathogenesis to treatment.

Authors:  Cosimo Bruni; Giovanna Cuomo; Francesca W Rossi; Emanuela Praino; Silvia Bellando-Randone
Journal:  J Scleroderma Relat Disord       Date:  2018-04-04

8.  Deterioration of renal function in hypertensive patients with scleroderma despite blood pressure normalization with captopril.

Authors:  B Waeber; M D Schaller; J P Wauters; H R Brunner
Journal:  Klin Wochenschr       Date:  1984-08-01

9.  Scleroderma renal crisis.

Authors:  L Michael Prisant; Don H Loebl; Laura L Mulloy
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Mar-Apr       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.